New combo therapy shows promise for Hard-to-Treat cancers
Disease control
Completed
This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…
Phase: PHASE2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated May 12, 2026 13:41 UTC